NCT05124561撤回3 期
A Multicenter, Randomized, Double-blind, Parallel-controlled Phase III Clinical Trial on the Efficacy, Safety, and Immunogenicity of Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation (Ad5-nCoV-IH) in Adults Aged 18 Years and Above Who Have Received One Dose of Intramuscular Ad5-nCoV
适应症
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 主要终点
- Incidence of COVID-19 cases.
研究概览
简要总结
This phase III clinical trial is an endpoint-driven randomized, double-blind, parallel-controlled, multicenter clinical trial, and around 13,000 subjects aged 18 years and above who have previously received 1 dose of intramuscular Ad5-nCoV will be recruited. Volunteers should have been vaccinated with intramuscular Ad5-nCoV > 56 days prior to enrollment. All subjects will receive 1 dose of investigational vaccine or placebo through nebulized inhalation. The ratio of subjects in the vaccine group and placebo group is 1:1 and the efficacy and safety of the investigational vaccine will be followed up for 52 weeks after vaccination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adult volunteers aged 18 years and above who have received 1 dose of intramuscular Ad5-nCoV > 56 days at the enrollment.
- •Volunteers who have provided informed consent and signed the informed consent form.
- •Volunteers who are able and willing to comply with the requirements of the clinical study protocol, and can complete the entire follow-up period of this study.
排除标准
- •Allergic to the active ingredient, any non-active ingredient, or substances used in the manufacturing process, or developed an allergy to similar vaccines in the past.
- •History of severe anaphylactic reaction to vaccines (e.g., acute anaphylactic reactions, angioedema, dyspnea).
- •History or family history of seizures, epilepsy, encephalopathy, or psychosis.
- •Severe nasal or oral diseases, such as acute rhinitis (sinusitis), allergic rhinitis, oral ulcers, throat redness, and swelling.
- •History of a definite diagnosis of COVID-
- •Positive SARS-CoV-2 N antibody rapid screening kit (IgG and IgM) results.
- •Received COVID-19 vaccine other than Ad5-nCoV.
- •Axillary temperature > 37.0°C.
- •Severe cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, or severe hypertension and cannot be controlled by drugs.
- •Lung function abnormalities such as asthma, chronic obstructive pulmonary disease, and pulmonary fibrosis.
- •Acute febrile illness, symptoms of upper respiratory tract infection, or infectious diseases.
- •Severe chronic diseases, or diseases of the progressive stage that cannot be steadily controlled, such as diabetes or thyroid disorders.
- •Asplenia or functional asplenia.
- •Thrombocytopenia or other coagulation disorder.
- •Received immunosuppressant or immunomodulatory therapy (continuous oral or intravenous infusion for more than 14 days), anti-allergic therapy, cytotoxic therapy within the past 6 months. Inhalational and local steroids are allowed.
- •Received blood products within 4 months before receiving the investigational vaccine.
- •Received other vaccines within the past 14 days or plan to receive other vaccines 14 days after scheduled immunization with the investigational vaccine.
- •Volunteers under antituberculous treatment or with active tuberculosis.
- •Received blood/plasma products or immunoglobulin 60 days before immunization with the investigational vaccine or planned to receive blood/plasma products or immunoglobulin during the entire study period.
- •Females who are positive for the urine pregnancy test, pregnant, or breastfeeding, or females who plan to conceive within 3 months (urine pregnancy test will only be performed in female volunteers of childbearing age).
- •Volunteers who are judged by the investigator with any contradiction to the study protocol or affected the signing of informed consent due to various medical, psychological,social, or other conditions.
结局指标
主要结局
Incidence of COVID-19 cases.
时间窗: Day 14 to 12 months post vaccination
The efficacy of Ad5-nCoV-IH in preventing virologically confirmed (PCR positive) COVID-19 disease.
Incidence of SAE
时间窗: Within 12 months post vaccination
Evaluate the incidence of severe adverse events (SAE)
次要结局
- Incidence of COVID-19 cases(Day 28 to 12 months post vaccination)
- Incidence of Adverse Events (AEs)(Within 28 days post vaccination)
- Incidence of severe COVID-19 cases(Day 14 and Day 28 to 12 months post vaccination)
- Incidence of COVID-19 cases in different age groups(Day 14 and Day 28 to 12 months post vaccination)
- Incidence of Adverse Reactions (ARs)(Within 14 days post vaccination)
- Immunogenicity of neutralizing antibodies(Day 14, Day 28, Week 24, and Week 52 post-vaccination)
- Immunogenicity of S-RBD IgG antibody (ELISA method)(Day 14, Day 28, Week 24, and Week 52 post-vaccination)
研究者
相似试验
已完成
3 期
A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque PsoriasisModerate to Severe Chronic Plaque PsoriasisNCT05975268Shanghai Junshi Bioscience Co., Ltd.747
已完成
3 期
Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderate to Severe Chronic Atopic Dermatitis(AD)Atopic DermatitisNCT03269773Kang Stem Biotech Co., Ltd.197
进行中（未招募）
3 期
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight SubjectsObesity/OverweightNCT06728124Gan & Lee Pharmaceuticals.630
进行中（未招募）
3 期
Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.HER2-positive Breast CancerNCT05985187Chia Tai Tianqing Pharmaceutical Group Co., Ltd.412
已完成
3 期
A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and AboveCOVID-19NCT04510207China National Biotec Group Company Limited44,101